Skip to main content

Table 1 Characteristics of the included studies

From: Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis

Author Country Year Study design Stage Total no. MSI-H MSS MSI determination Survival information Chemotherapy
Alex, A.K [12] Brazil 2017 Non-RCT IV 126 42 84 IHC + PCR OS Oxaliplatin-based
Bertagnolli [10] USA 2009 RCT III 702 96 606 IHC + PCR OS, DFS FU/LV/IFL
Chouhan [13] Australia 2018 Non-RCT III 686 95 591 IHC + PCR CSS NA
des Guetz [14] France 2007 Non-RCT IV 40 9 31 PCR OS FOLFOX
Drucker [15] Canada 2013 Non-RCT III 159 18 141 IHC + PCR OS, DFS FOLFOX/capecitabine
Elsaleh [16] Australia 2001 Non-RCT III 732 63 669 PCR OS 5-FU/levamisole
Fujiyoshi [17] Japan 2017 Non-RCT IV 401 15 386 PCR OS NA
Guidoboni [7] Italy 2001 Non-RCT III 54 20 34 PCR OS 5-FU
Hemminki [18] Finland 2000 Non-RCT III 95 11 84 PCR OS, DFS 5-FU-based
Jover [19] Spain 2006 Non-RCT III 209 18 191 IHC + PCR OS, DFS 5-FU-based
Jung [20] Korea 2016 Non-RCT III 60 19 41 PCR CSS NA
Kim, C.G [21]. Korea 2016 Non-RCT III 2940 261 2679 PCR OS, DFS 5-FU/LV/FOLFOX
Kim, J.E [22]. Korea 2011 Non-RCT IV 197 23 174 IHC + PCR OS, DFS FOLFIRI/XELIRI
Kim, J.E [23]. Korea 2017 Non-RCT III and IV 795 73 722 PCR OS, DFS FOLFOX
Kim, S.H [24]. Korea 2013 Non-RCT III 394 26 368 PCR DFS FOLFOX
Klingbiel, D [6]. Switzerland 2015 RCT III 859 104 755 PCR OS, DFS 5-FU/LV/FOLFIRI
Li, P [25]. China 2017 Non-RCT III and IV 599 54 545 IHC OS, DFS FOLFOX/XELOX
Liu [26] China 2018 Non-RCT IV 461 30 431 IHC + PCR OS, DFS NA
Ma, J [27]. China 2015 Non-RCT IV 184 34 150 IHC OS, PFS FOLFIRI/irinotecan
Malesci, A [28]. Italy 2007 Non-RCT III 264 27 237 PCR DSS 5-FU
Mohan, H.M [29]. Ireland 2016 Non-RCT III 320 32 288 IHC + PCR OS, DSS NA
Nopel-Dunnebacke [30] Germany 2014 RCT IV 204 14 190 IHC + PCR OS, PFS CAPOX/FUFOX
Nordholm-Carstensen [31] Denmark 2015 RCT IV 935 75 860 IHC OS NA
Oh, S.Y [32]. Korea 2013 Non-RCT III 127 16 111 PCR OS, DFS FOLFOX
Sasaki, Y [33]. Japan 2016 RCT III 304 23 281 IHC OS, RFS UFT
Sinicrope, F. A [34] USA 2011 RCT III 1363 180 1183 IHC + PCR OS, DFS 5-FU-based
Sinicrope, F.A [35]. USA 2013 RCT III 2580 314 2266 IHC + PCR DFS FOLFOX-based
Taieb, J [36]. France 2016 RCT III 1791 177 1614 IHC + PCR OS, DFS FOLFOX ± cetuximab
Tan, W. J [37]. Singapore 2018 Non-RCT III 299 27 272 IHC DSS, RFS 5FU/capecitabine ± oxaliplatin
Tran, B [38]. Australia 2011 Non-RCT IV 350 40 310 IHC + PCR OS NA
Venderbosch, S [8]. Netherlands 2014 RCT III 3063 153 2910 IHC OS, PFS NA
Watanbe [39] USA 2000 Non-RCT III 229 73 156 PCR OS, DFS 5-FU–based
Westra, J. L. [40] UK 2005 RCT III 273 229 44 PCR DFS 5-FU–based
Wright, C.M [41]. Australia 2000 Non-RCT III 238 21 217 PCR OS NA
Zaanan, A [42]. France 2010 Non-RCT III 233 32 201 IHC + PCR DFS FOLFOX
Zaanan, A [43]. France 2011 Non-RCT III 303 34 269 IHC + PCR OS, DFS FOLFOX
  1. MSI-H microsatellite instability-high, MSS microsatellite stable, RCT randomized controlled trial, IHC immunohistochemistry, PCR polymerase chain reaction, OS overall survival, DFS disease-free survival, DSS disease-specific survival, CSS cancer-specific survival, RFS recurrence-free survival, FU fluorouracil, LV leucovorin, IFL irinotecan + fluorouracil + leucovorin, 5-FU 5-fluorouracil, FOLFOX 5-fluorouracil + leucovorin + oxaliplatin, FOLFIRI 5-fluorouracil + irinotecan + leucovorin, XELOX xeloda + oxaliplatin, CAPOX capecitabine + oxaliplatin, FUFOX fluorouracil + fludarabine + oxaliplatin, UFT tegafur